

## United States Patent and Trademark Office



UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virgains 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/488,491	01/20/2000	Michel F. Levesque	CEDAR 042638	4505
75	90 10/21/2003		EXAM	INER
Edward G. Poplawski, Esq. Sidley Austin Brown & Wood LLP 555 West Fifth Street Los Angeles, CA 90013-1010			SCHULTZ, JAMES	
			ART UNIT	PAPER NUMBER
			1635 ·	26
			DATE MAILED: 10/21/2003	3

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)
	09/488,491	LEVESQUE ET AL.
Offic Action Summary	Examiner	Art Unit
	J. Douglas Schultz	1635
The MAILING DATE of this communication	on appears on the cover sheet with	the correspondence address
A SHORTENED STATUTORY PERIOD FOR IT THE MAILING DATE OF THIS COMMUNICAT  - Extensions of time may be available under the provisions of 37 after SIX (6) MCNTHS from the mailing date of this communicat  - If the period for reply specified above, the maximum statutory  - Failure to reply within the set or extended period for reply wifl, b  - Any reply received by the Office later than three months after the earmed patent term adjustment. See 37 CFR 1.704(b).  Status	TION.  CFR 1.136(a). In no event, however, may a reption.  s, a reply within the statutory minimum of thirty or period will apply and will expire SIX (6) MONTH statute. Cause the application to become ABAI	oly be timely filed  (30) days will be considered timely.  15 from the mailing date of this communication.  NDONED (35 U.S.C. & 133).
1) Responsive to communication(s) filed o	on 22 October 2002 .	
·— · · · · · · · · · · · · · · · · · ·	☐ This action is non-final.	
3) Since this application is in condition for		ers, prosecution as to the ments is
closed in accordance with the practice of Disposition of Claims	under Ex parte Quayle, 1935 C.D.	. 11, 453 O.G. 213.
4) Claim(s) 1-11,15,17,19,22,23,27-30,33-	36,39,43-45,47 and 49-66 is/are p	pending in the application.
4a) Of the above claim(s) is/are wi	ithdrawn from consideration.	
5) Claim(s) is/are allowed.		
6) Claim(s) is/are rejected.		
7) Claim(s) is/are objected to.		
8) Claim(s) See Continuation Sheet are sub	eject to restriction and/or election	requirement.
Application Papers		2 000
9)☐ The specification is objected to by the Exa	aminer.	
10) ☐ The drawing(s) filed on is/are: a) ☐	accepted or b) objected to by the	e Examiner.
Applicant may not request that any objection	n to the drawing(s) be held in abeyan	ce. See 37 CFR 1.85(a).
11) The proposed drawing correction filed on	is: a) ☐ approved b) ☐ dis	approved by the Examiner.
If approved, corrected drawings are required	· •	
12) ☐ The oath or declaration is objected to by the	he Examiner.	
Priority under 35 U.S.C. §§ 119 and 120		
13) Acknowledgment is made of a claim for for	oreign priority under 35 U.S.C. §	119(a)-(d) or (f).
a) ☐ All b) ☐ Some * c) ☐ None of:		
1. Certified copies of the priority docu	ments have been received.	
2. Certified copies of the priority docu	ıments have been received in App	olication No
<ul> <li>Copies of the certified copies of the application from the Internation</li> <li>See the attached detailed Office action for</li> </ul>	al Bureau (PCT Rule 17.2(a)).	-
14)☐ Acknowledgment is made of a claim for do		
a) ☐ The translation of the foreign languag	ge provisional application has bee	n received.
Attachment(s)	,	<u> </u>
1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-94 3) Information Disclosure Statement(s) (PTO-1449) Paper N	l8) 5) 🔲 Notice of Info	mmary (PTO-413) Paper No(s)  prmal Patent Application (PTO-152)
S. Patent and Trademark Office TOL-326 (Rev. 04-01) Off	fice Action Summary	Part of Paper No. 10

Continuation of Disposition of Claims: Claims subject to restriction and/or election requirement are 1-11,15,17,19,22,23,27-30,33-36,39,43-45,47 and 49-66.

Application/Control Number: 09/488,491

Art Unit: 1635

Page 2

## **DETAILED ACTION**

Applicants election of group II and subsequent cancellation of non-elected subject matter has been noted and fully entered. Election was made without traverse in Paper No. 25, entered October 22, 2002.

The Office has determined that, through inadvertent error, the Office action mailed July—
17, 2002 requiring restriction did not properly distinguish subject matter contained in the previously identified Groups I-III that is considered to be directed to distinct inventions as defined below. Accordingly, a supplemental restriction requirement is issued below.

## Election/Restrictions

Restriction to one of the following inventions is required under 35 U.S.C. 121:

- I. Claims 1-11, 15, 43-5, 47, and 49-60, drawn to methods of transdifferentiating cells of epidermal origin into cells possessing neuron-like characteristics and kits pertaining thereto, classified in class 435, subclass 325.
- II. Claims 17, 19, 22, 23, 27-30, 33-36, 39, and 61-66, drawn to cells of epidermal origin having one or more morphological, physiological and/or immunological features of a neuronal cell produced by the methods of group I, classified in class 435, subclass 325 The inventions are distinct, each from the other because of the following reasons:

Application/Control Number: 09/488,491

Art Unit: 1635

Inventions I and II are related as process of making and product made. The inventions are distinct if either or both of the following can be shown: (1) that the process as claimed can be used to make other and materially different product or (2) that the product as claimed can be made by another and materially different process (MPEP § 806.05(f)). In the instant case the cells of group II can be made by transfecting basal epidermal cells with a vector containing one of the immunologically detected proteins. Such a process has no steps in common with the claimed methods, and would result in a cell of epidermal origin, cultured *in vitro*, that would possess the requisite features claimed by applicant.

Furthermore, a search for art against both the method and the product made would be burdensome, because the cells as claimed in the product-by-process format as currently recited read on any cell that is of epidermal origin that may express any of the marker proteins recited or express neuritic outgrowths. Such a search is distinct and does not overlap with the search for methods of treating cells *ex vivo* with growth factors and antisense inhibitors to change cellular phenotype.

Because these inventions are distinct for the reasons given above and the search required for Group I is not required for Group II, restriction for examination purposes as indicated is proper.

Because these inventions are distinct for the reasons given above and have acquired a separate status in the art because of their recognized divergent subject matter, restriction for examination purposes as indicated is proper.

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the

Application/Control Number: 09/488,491

Art Unit: 1635

currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to J. Douglas Schultz whose telephone number is 703-308-9355. The examiner can normally be reached on 8:00-4:30 M-F.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, John L. LeGuyader can be reached on 703-308-0447. The fax phone number for the organization where this application or proceeding is assigned is (703) 872-9306.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is 703-308-0196.

James Douglas Schultz, PhD

ANDREW WANG SUPERVISORY PATENT EXAMINER TECHNOLOGY CENTER 1600